Serum TSH level may predict survival of hepatitis B related liver failure patients

Recently conducted research found that there is a significant correlation between serum Thyroid-stimulating hormone levels and Hepatitis B virus-related Acute-on-Chronic Liver Failure patients' survival rates. The study was published in the journal 'BMC Gastroenterology.' 

Acute-on-chronic Liver disease (ACLF) is a complicated condition caused due to acute deterioration of known or unknown chronic liver diseases caused by the Hepatitis B virus. Studies in the past evaluated the association between ACLF and other systemic disorders but there were no studies on the endocrine system. So, researchers from China and U.K. conducted a study to analyze the effect of serum thyroid-stimulation hormone (TSH) levels on the prognosis of patients with hepatitis B virus (HBV)-related ACLF. 

A retrospective cohort study was performed on 1,862 patients with HBV-related ACLF. The study data was collected from the "Survival Cohort Study (SCS)" which was registered at ClinicalTrials.gov. Using Cox proportional hazards regression, risk factors associated with 30-day and 90-day survival, hazard ratios (HRs), and 95% confidence intervals (CIs) for TSH were estimated. Obtaining the Area Under the ROC curve (AUROC) analysis, the cut-off values were calculated. Survival was compared between the groups using the log-rank test.